Efficacy And Safety Of Anti-VEGF For Macular Oedema Secondary To Retinal Vein Occlusion:a Meta Analysis

Objective: Evaluate the efficacy and safety of anti-VEGF in the treatment of macular edema secondary to retinal vein occlusion by Meta analysis.Methods:Eligible studies were identified via a systematic searching of databases,including CNKI?Wanfang database?VIP?Pubmed?EMBASE and the Cochrane Library,date from inception up to December 30,2016.According to the inclusion and exclusion criteria,randomized clinical control trials of patients with macular edema secondary to retinal vein occlusion who treated with anti-VEGF were included.Literature quality assessment using Cochrane's bias risk assessment tool.We use Rev Man 5.3 to carry out the meta analysis.The final result is represented by forest plots.Discussion and conclusion were based on the results of analyses.Results:Fifteen RCTS were included in the study with a total of 1831 eyes,Meta analysis showed:1.CRVO: Compared with the sham injection group,anti-VEGF can significantly improve the visual acuity and reduce macular edema,there is a statistically significant difference between the groups.After 6 months of treatment,the mean changes in BCVA and CRT from baseline between the two groups were15.42 ETDRS letters(95%CI=13.52-17.32)and-263.03 m(95%CI=-317.97--208.09);2.BRVO:Compared with GLP group,anti-VEGF can significantly improve the visual acuity and reduce macular edema,there are significant differences between groups.After 6 months of treatment,the mean changes in BCVA and CRT from baseline between the two groups were 9.21 ETDRS letters(95%CI=7.52-10.91)and-187.05 m(95%CI=-236.91--137.19);3.adverse events: anti-VEGF theray can reduce neovascular complications,there were significant differences when compare with control group in the follow-up period 6 months(RR=0.17,95%CI=0.07-0.41),other adverse events in two groups were not statistically significant.Conclusion : Intravitreal anti-VEGF injection has definite effect on improving BCVA and reducing CRT for macular oedema secondary to retinal vein occlusion,and can prevent neovascular complications without any correlation in ocular or systemic adverse events.